DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vfend (Voriconazole) - Published Studies

 
 



Vfend Related Published Studies

Well-designed clinical trials related to Vfend (Voriconazole)

The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. [2013]

Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. [2011.07]

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. [2011.01]

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. [2010.12.09]

Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis. [2010.12]

Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. [2010.11]

Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. [2010.11]

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. [2010.11]

Comparison of natamycin and voriconazole for the treatment of fungal keratitis. [2010.06]

Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. [2010.06]

Comparison of natamycin and voriconazole for the treatment of fungal keratitis. [2010]

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. [2009.12]

Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. [2009.12]

Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole. [2009.11]

Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. [2009.04]

Penetration of 1% voriconazole eye drops into human vitreous humour: a prospective, open-label study. [2009.03]

Voriconazole drastically increases exposure to oral oxycodone. [2009.03]

Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. [2009.02]

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. [2009.01]

Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. [2009.01]

Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. [2008.02]

An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. [2007.12.01]

Effect of voriconazole on the pharmacokinetics of diclofenac. [2007.12]

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). [2007.11]

Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. [2007.10]

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. [2007.09]

Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. [2007.07.23]

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. [2007.07.01]

Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. [2007.02]

Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. [2007.01]

Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. [2006.11]

Pharmacokinetic interaction between voriconazole and methadone at steady-state in patients on methadone therapy. [2006.10.30]

Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. [2006.08]

Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. [2006.06]

Pharmacokinetics of voriconazole after oral and intravenous administration to horses. [2006.06]

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. [2006.04]

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. [2005.10.22]

No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. [2003.12]

Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. [2003.12]

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. [2002.09]

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. [2002.08.08]

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. [2002.08]

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. [2002.04]

Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. [2002.04]

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. [2002.01.24]

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. [2001.11.01]

Well-designed clinical trials possibly related to Vfend (Voriconazole)

In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial. [2014]

Predictors of outcome in fungal keratitis. [2012]

Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial. [2012]

Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. [2011.05]

Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. [2010.01]

Changes in causes of death over time after treatment for invasive aspergillosis. [2008.05.15]

Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. [2007.05]

The debate: The trials have told us very little. [2006.09]

Other research related to Vfend (Voriconazole)

Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation. [2013]

Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial. [2013]

Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. [2012]

Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. [2011.12]

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukaemia /myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. [2011.11.04]

Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. [2011.11.03]

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. [2011.11]

Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. [2011.11]

Intravitreally implantable voriconazole delivery system for experimental fungal endophthalmitis. [2011.10]

Resolution of galactomannan antigenemia in a patient receiving oral voriconazole for chronic necrotizing pulmonary aspergillosis. [2011.08]

Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. [2011.07.26]

Quality control guidelines for amphotericin B, Itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with nonsupplemented Mueller-Hinton Agar (CLSI M51-A document) for nondermatophyte Filamentous Fungi. [2011.07]

[A case of lung scedosporiosis successfully treated with monitoring of plasma voriconazole concentration level]. [2011.05]

Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation. [2011]

Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. [2011]

Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. [2010.10]

Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). [2010.09.08]

Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan. [2010.08.24]

Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application. [2010.07]

Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. [2010.06]

[Voriconazole compromises renal function in an elderly CDK patient with Candida albicans infection] [2010.05]

A case series of unilateral orbital aspergillosis in three cats and treatment with voriconazole. [2010.05]

X-linked chronic granulomatous disease with voriconazole-induced photosensitivity/ photoaging reaction. [2010.05]

Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing. [2010.02]

Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. [2010]

Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. [2010]

Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. [2010]

Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. [2009.09.21]

Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model. [2009.09]

Successful voriconazole treatment of invasive pulmonary aspergillosis in a patient with acute biphenotypic leukemia. [2009.08]

Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole. [2009.07]

Use of voriconazole in the surgical management of chronic postoperative fungal endophthalmitis. [2009.07]

Prospective open-label study of the administration of two-percent voriconazole eye drops. [2009.07]

Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin. [2009.06]

Intracameral voriconazole: in vitro safety for human ocular cells. [2009.04.28]

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. [2009.02]

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. [2009.01]

Neuroaspergillosis in an immunocompetent patient successfully treated with voriconazole and a corticosteroid. [2009]

Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses. [2009]

Early detection of breakthrough trichosporonosis by serum PCR in a cord blood transplant recipient being prophylactically treated with voriconazole. [2008.12]

Paecilomyces lilacinus peritonitis complicating peritoneal dialysis cured by oral voriconazole and terbinafine combination therapy. [2008.12]

Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. [2008.12]

[Clinical features of chronic necrotizing pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease] [2008.11]

Voriconazole drastically increases exposure to oral oxycodone. [2008.10.03]

[Case of orbital apex syndrome caused by invasive aspergillosis successfully treated during the diagnostic procedure by the use of voriconazole] [2008.10]

Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. [2008.09]

Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. [2008.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014